Market Opportunity Large unmet need in smell and taste restoration with no marketed therapies, presenting a sizable addressable market in the US and Europe that sales teams can target with clinical evidence and partnering discussions.

Clinical Validation Phase 2 randomized trial for CYR-064 with readout expected in Q1'25 and prior pilot data in 92 patients; leverage data to engage KOLs, payers, and potential collaborators seeking proof of concept and regulatory progress.

Clinical Partnerships Active participation in major industry events (BIO International Convention, ARS meeting) and ongoing multicenter trial across 14 US sites; use these milestones to coordinate outreach to academic centers, contract research organizations, and potential licensees.

Funding & Growth Funding history includes multiple rounds totaling around $22M and a recent Series B, signaling investor confidence; pursue strategic partnerships or co-development deals to accelerate late-stage development and commercialization.

Competitive Positioning Unique intranasal formulation addressing a condition with no approved therapies; emphasize first-mover advantage and potential for rapid differentiation in discussions with large pharma and specialty biotech players seeking orphan- or neurology-related franchises.